Interpace Biosciences announces preliminary Q4 revenue of $10.3M

• Interpace Biosciences (OTCQX:IDXG) on Thursday said for the fourth quarter, it reported revenue of $10.3 million and income from continuing operations of $0.8 million, a $2.2 million improvement over the prior year quarter’s loss of $1.4 million.
• For the full year 2023, revenue and income from continuing operations were $40.2 million and $1.1 million, respectively.
• For FY23, revenue increased 26% over the prior year, driven by increased volume, additional commercial contracts, and collection initiatives.
• The company reported Q4 and FY Adjusted EBITDA of $1.5 million and $5.4 million; a $6.6 million and 463% increase year-over-year.
• Source: Press Release

More on Interpace Biosciences

• Financial information for Interpace Biosciences